Andrew Regan - 08 Dec 2025 Form 4 Insider Report for CDT Equity Inc. (CDT)

Role
Chief Executive Officer, Director, 10%+ Owner
Signature
/s/ Andrew Regan
Issuer symbol
CDT
Transactions as of
08 Dec 2025
Net transactions value
+$402,761
Form type
4
Filing time
22 Dec 2025, 16:05:28 UTC
Previous filing
22 Sep 2025
SEC
View on sec.gov

Reporting Owners (2)

Name Relationship Address Signature Signature date CIK
Regan Andrew Chief Executive Officer, Director, 10%+ Owner 4851 TAMIAMI TRAIL NORTH, SUITE 200, NAPLES /s/ Andrew Regan 22 Dec 2025 0001991325
Corvus Capital Ltd. 10%+ Owner FLOOR 2, WILLOW HOUSE, CRICKET SQUARE, P.O. BOX 709,, GRAND CAYMAN, CAYMAN ISLANDS CORVUS CAPITAL LTD. By: /s/ Andrew Regan, Name: Andrew Regan, Title: Chief Executive Officer 22 Dec 2025 0001990829

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CDT Common Stock Award $402,392 +224,800 +8978% $1.79 227,304 08 Dec 2025 By Corvus Capital Ltd. F1, F2, F3, F6
holding CDT Common Stock 140,005 08 Dec 2025 Direct
holding CDT Common Stock 19,349 08 Dec 2025 By Manoira Corporation F4, F6
holding CDT Common Stock 14 08 Dec 2025 By Algo Holdings, Inc. F5, F6

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CDT Pre-Funded Warrants Award $369 +3,685,815 $0.000100 3,685,815 08 Dec 2025 Common Stock 3,685,815 $0.000100 By Corvus Capital Ltd. F1, F3, F6, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On December 8, 2025, CDT Equity Inc. (the "Company") and Corvus Capital Limited ("Corvus") entered into a Sale and Purchase Agreement, pursuant to which the Company issued to Corvus 224,800 shares of common stock, par value $0.0001 per share of the Company, and pre-funded warrants to purchase up to 3,685,815 shares of Common Stock (the "Pre-Funded Warrants"), pursuant to the acquisition of Conduit Pharmaceuticals Limited and its liabilities.
F2 Based on the closing price per share of Common Stock on December 7, 2025.
F3 These shares of Common Stock are owned of record by Corvus.
F4 These shares of Common Stock are owned of record by Manoira Corporation ("Manoira").
F5 These shares of Common Stock are owned of record by Algo Holdings, Inc. ("Algo").
F6 Corvus is the owner of 99.0% of the equity interests of Manoira and Algo is a wholly owned subsidiary of Corvus, and, therefore, may also be deemed to beneficially own the shares of Common Stock held of record by Manoira and Algo. Dr. Regan is the sole director of Manoira and the Chief Executive Officer and sole shareholder of Corvus. By virtue of these relationships, Dr. Regan may be deemed to beneficially own the shares of Common Stock held of record by Manoira, Algo and Corvus. Each of Corvus and Dr. Regan disclaims any such beneficial ownership, including with respect to the Pre-Funded Warrant Shares, except to the extent of its or his pecuniary interest therein.
F7 Until exercised in full.